<?xml version="1.0" encoding="UTF-8"?>
<p id="para3640">The price of drug treatment and medical services that are not supported by the Pharmaceutical Benefits Scheme represents another barrier to tackling the burden of liver disease—eg, new obesity drugs such as naltrexone–bupropion. Policy makers need to recognise that liver diseases are chronic diseases and to establish nurse-led community-based models of care. Finally, enhancing funding for medical research to identify novel therapeutic targets for treating specific liver diseases, such as alcohol-related liver disease, NASH, and hepatitis B, and for implementation research is crucial.</p>
